Ventyx Biosciences, Inc. (NASDAQ:VTYX) Insider John Nuss Sells 13,161 Shares

Ventyx Biosciences, Inc. (NASDAQ:VTYX - Get Free Report) insider John Nuss sold 13,161 shares of Ventyx Biosciences stock in a transaction dated Thursday, December 19th. The stock was sold at an average price of $2.26, for a total value of $29,743.86. Following the completion of the transaction, the insider now directly owns 485,701 shares of the company's stock, valued at approximately $1,097,684.26. This trade represents a 2.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Ventyx Biosciences Stock Performance

Ventyx Biosciences stock traded down $0.02 during mid-day trading on Thursday, reaching $2.28. The stock had a trading volume of 1,760,269 shares, compared to its average volume of 2,039,973. The firm has a market capitalization of $161.22 million, a PE ratio of -0.97 and a beta of 0.48. Ventyx Biosciences, Inc. has a fifty-two week low of $1.67 and a fifty-two week high of $11.48. The stock's 50-day simple moving average is $2.30 and its 200-day simple moving average is $2.40.

Institutional Trading of Ventyx Biosciences

A number of hedge funds and other institutional investors have recently bought and sold shares of VTYX. Deerfield Management Company L.P. Series C grew its holdings in shares of Ventyx Biosciences by 64.6% during the second quarter. Deerfield Management Company L.P. Series C now owns 5,829,570 shares of the company's stock valued at $13,466,000 after buying an additional 2,287,570 shares during the last quarter. Sio Capital Management LLC boosted its stake in Ventyx Biosciences by 153.2% during the 3rd quarter. Sio Capital Management LLC now owns 1,971,948 shares of the company's stock valued at $4,299,000 after purchasing an additional 1,193,024 shares during the last quarter. Vestal Point Capital LP increased its holdings in Ventyx Biosciences by 31.2% during the 3rd quarter. Vestal Point Capital LP now owns 1,725,000 shares of the company's stock worth $3,760,000 after purchasing an additional 410,000 shares in the last quarter. Acadian Asset Management LLC purchased a new stake in shares of Ventyx Biosciences in the second quarter worth approximately $608,000. Finally, XTX Topco Ltd bought a new position in shares of Ventyx Biosciences in the third quarter valued at approximately $246,000. Institutional investors own 97.88% of the company's stock.

Wall Street Analyst Weigh In

VTYX has been the subject of a number of research analyst reports. HC Wainwright reiterated a "neutral" rating and issued a $6.00 target price on shares of Ventyx Biosciences in a report on Monday, November 11th. Oppenheimer reiterated an "outperform" rating and set a $9.00 target price (down previously from $10.00) on shares of Ventyx Biosciences in a research report on Friday, November 8th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $10.00.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.